Emergence and management of drug-resistant enterococcal infections

Vista sencilla de ítem
dc.contributor.authorArias, Cesar A.
dc.contributor.authorMurray, Barbara E.
dc.date.accessioned2020-12-04T19:56:27Z
dc.date.available2020-12-04T19:56:27Z
dc.date.issued2008
dc.description.abstractenglishThe treatment of multidrug-resistant enterococcal infections continues to be a challenge for clinicians. Glycopeptide and beta-lactam resistance is now a common feature of the majority of Enterococcus faecium hospital isolates, and resistance to aminoglycosides, quinupristin-dalfopristin, linezolid and daptomycin further complicates the problem. New antibiotics, such as tigecycline, lipoglycopeptides (dalbavancin, oritavancin and telavancin) and cephalosporins with activity against Enterococcus faecalis (ceftobiprole and ceftaroline), may have potential activity against certain resistant enterococcal strains in specific clinical settings, as may some older antibiotics, such as ampicillin, chloramphenicol, doxycycline, minocycline and nitrofurantoin. However, the treatment of endovascular infections (particularly endocarditis, where bactericidal therapy is important for optimal cure rates) caused by resistant enterococci continues to be an immense challenge even with the availability of new agents. The optimal therapy for these infections is not well established and clinical data are usually limited to case reports with conflicting results. Therefore, treatment decisions may have to be based on animal models and sporadic experiences and the best approach is for the physician to consider carefully each patient on a case by case manner and gather all the clinical and microbiological information possible regarding species identification and susceptibilities in order to choose a therapeutic regimen that would appear to be active.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1586/14787210.6.5.637
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1744-8336
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/5178
dc.language.isoeng
dc.publisherTaylor & Francisspa
dc.publisher.journalExpert Review of Anti-infective Therapyspa
dc.relation.ispartofseriesExpert Review of Anti-infective Therapy, 1744-8336, Vol. 6, Nro. 5, 2008 p. 637-655spa
dc.relation.urihttps://www.tandfonline.com/doi/full/10.1586/14787210.6.5.637
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2008-10
dc.rights.localAcceso abiertospa
dc.subject.keywordsEnterococcus spp.spa
dc.subject.keywordsResistancespa
dc.subject.keywordsTherapyspa
dc.subject.keywordsVancomycin resistancespa
dc.titleEmergence and management of drug-resistant enterococcal infectionsspa
dc.title.translatedEmergence and management of drug-resistant enterococcal infectionsspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Arias_Cesar_A_2008.pdf
Tamaño:
519.82 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos